Apr 09, 2018 4:45 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 22, 2018 4:30 pm EDT Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
Mar 16, 2018 8:00 am EDT Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Mar 06, 2018 4:05 pm EST Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
Feb 27, 2018 7:00 am EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress
Feb 21, 2018 4:06 pm EST Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
Jan 10, 2018 8:00 am EST Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis